Investor Presentation
8
Investor presentation First six months of 2022
GLP-1 class expansion continues in the US as new prescriptions
have accelerated in the second quarter of 2022
US GLP-1 weekly NBRx prescriptions
Weekly NBRX
scripts ('000)
50
50
40
40
30
20
10
0
July
2020
OzempicⓇ
TRX share
80%
60%
48.7%
40%
20%
0%
July
2022
July
2020
RybelsusⓇ
- VictozaⓇ
NN GLP-1
dulaglutide
Novo NordiskⓇ
US GLP-1 TRX market share
Total GLP-1
Class growth >35%
scripts
('000)
4,000
⚫tirzepatide
56.4% 3,000
40.7%
2,000
40.6%
7.9%
1,000
7.7%
1.1%
0
July
2022
Total monthly GLP-1 scripts
Source: IQVIA Xponent, Weekly (ending 15 July 2022) Each data points represents a rolling four-week average. Total GLP-1 scripts constitute all prescriptions of GLP-1 medications in the market and have the full month of July as latest available data point
NBRX: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions
Note: Class growth calculated as Q2 2022 vs Q2 2021View entire presentation